Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 Contraindications  





3 Adverse effects  





4 Mechanism of action  





5 Nomenclature  





6 References  














Indometacin






العربية
Asturianu
تۆرکجه

Bosanski
Čeština
Cymraeg
Deutsch
Eesti
Ελληνικά
Español
فارسی
Français

Հայերեն
Bahasa Indonesia
Italiano
Magyar
Nederlands

Norsk bokmål
ି
پښتو
Polski
Português
Română
Русский
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
ி

Türkçe
Українська
Tiếng Vit

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Indometacin
Clinical data
Pronunciation/ɪndˈmɛtəsɪn/
Trade namesIndocid, Indocin
Other namesIndomethacin (USAN US)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU:C
  • Routes of
    administration
    By mouth, rectal, intravenous, topical
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: WARNING[1]Rx-only
  • Pharmacokinetic data
    Bioavailability~100% (oral), 80–90% (rectal)
    Protein binding99%[2]
    MetabolismLiver
    Elimination half-life2.6-11.2 hours (adults), 12-28 hours (infants)[2]
    ExcretionKidney (60%), fecal (33%)
    Identifiers
    • 2-{1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    PDB ligand
    CompTox Dashboard (EPA)
    ECHA InfoCard100.000.170 Edit this at Wikidata
    Chemical and physical data
    FormulaC19H16ClNO4
    Molar mass357.79 g·mol−1
    3D model (JSmol)
    • Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O

    • InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) checkY

    • Key:CGIGDMFJXJATDK-UHFFFAOYSA-N checkY

      (verify)

    Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.[2][3]

    It was patented in 1961 and approved for medical use in 1963.[4][5] It is on the World Health Organization's List of Essential Medicines.[6] In 2021, it was the 253rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

    Medical uses[edit]

    As an NSAID, indometacin is an analgesic, anti-inflammatory, and antipyretic. Clinical indications for indometacin include:
    Joint diseases

    Headaches

    Others

    Contraindications[edit]

    Adverse effects[edit]

    In general, the adverse effects of indometacin are similar to those of all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, which then inhibits the production of prostaglandins in the stomach and intestines responsible for maintaining the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors, can cause peptic ulcers. These ulcers can result in serious bleeding or perforation, requiring hospitalization of the patient.

    To reduce the possibility of peptic ulcers, indometacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50 and 200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indometacin.

    Many NSAIDs, but particularly indometacin, cause lithium retention by reducing its excretion by the kidneys. Thus indometacin users have an elevated risk of lithium toxicity. For patients taking lithium (e.g. for treatment of depressionorbipolar disorder), less toxic NSAIDs such as sulindacoraspirin are preferred.

    All NSAIDs, including indometacin, also increase plasma renin activity and aldosterone levels, and increase sodium and potassium retention. Vasopressin activity is also enhanced. Together these may lead to:

    Elevations of serum creatinine and more serious renal damage such as acute kidney failure, chronic nephritis and nephrotic syndrome, are also possible. These conditions also often begin with edema and high potassium levels in the blood.

    Paradoxically yet uncommonly, indometacin can cause headache (10 to 20%), sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal damage). There are unsubstantiated reports of worsening Parkinson's disease, epilepsy, and psychiatric disorders. Cases of life-threatening shock (including angioedema, sweating, severe hypotension and tachycardia as well as acute bronchospasm), severe or lethal hepatitis and severe bone marrow damage have all been reported. Skin reactions and photosensitivity are also possible side effects.

    The frequency and severity of side effects and the availability of better tolerated alternatives make indometacin today a drug of second choice. Its use in acute gout attacks and in dysmenorrhea is well-established because in these indications the duration of treatment is limited to a few days only, therefore serious side effects are not likely to occur.

    People should undergo regular physical examination to detect edema and signs of central nervous side effects. Blood pressure checks will reveal development of hypertension. Periodic serum electrolyte (sodium, potassium, chloride) measurements, complete blood cell counts and assessment of liver enzymes as well as of creatinine (renal function) should be performed. This is particularly important if Indometacin is given together with an ACE inhibitor or with potassium-sparing diuretics, because these combinations can lead to hyperkalemia and/or serious kidney failure. No examinations are necessary if only the topical preparations (spray or gel) are applied.

    Rare cases have shown that use of this medication by pregnant women can have an effect on the fetal heart, possibly resulting in fetal death via premature closing of the Ductus arteriosus.[14]

    In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[15][16] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[15][16]

    Mechanism of action[edit]

    Indometacin, a non-steroidal anti-inflammatory drug (NSAID), has similar mode of action when compared to other drugs in this group. It is a nonselective inhibitor of cyclooxygenase (COX) 1 and 2, the enzymes that participate in prostaglandin synthesis from arachidonic acid. Prostaglandins are hormone-like molecules normally found in the body, where they have a wide variety of effects, some of which lead to pain, fever, and inflammation. By inhibiting the synthesis of prostaglandins, indometacin can reduce pain, fever, and inflammation.[9] Indometacin mechanism of action, along with several other NSAIDs that inhibit COX, was described in 1971.[17]

    Additionally, indometacin has recently been found to be a positive allosteric modulator (PAM) of the CB1 cannabinoid receptor. By enhancing the binding and signalling of endogenous cannabinoids such as anandamide, PAMs may elicit increased cannabinergic signalling in a tissue specific manner, reducing the incidence of problematic side effects such as psychoactivity while maintaining some antinociceptive activity.[18]

    Besides, indometacin has logarithmic acid dissociation constant pKa of 3 to 4.5. Since the physiologic body pH is well above the pKa range of indometacin, most of the indometacin molecules will be dissociated into ionized form, leaving very little un-ionized form of indometacin to cross a cell membrane. If the pH gradient across a cell membrane is high, most of the indometacin molecules will be trapped in one side of the membrane with higher pH. This phenomenon is called "ion trapping". The phenomenon of ion trapping is particularly prominent in the stomach as pH at the stomach mucosa layer is extremely acidic, while the parietal cells are more alkaline. Therefore, indometacin are trapped inside the parietal cells in ionized form, damaging the stomach cells, causing stomach irritation. This stomach irritation can reduce if the stomach acidity is reduced, as the GI side effects from NSAIDs are generally reduced by decreasing stomach acidity.[9]

    Indometacin's role in treating certain headaches is unique compared to other NSAIDs. In addition to the class effect of COX inhibition, there is evidence that indometacin has the ability to reduce cerebral blood flow not only through modulation of nitric oxide pathways but also via intracranial precapillary vasoconstriction.[19] Indometacin property of reducing cerebral blood flow is useful in treating raised intracranial pressure. A case report has shown that an intravenous bolus dose of indometacin given with 2 hours of continuous infusion is able to reduce intracranial pressure by 37% in 10 to 15 minutes and increases cerebral perfusion pressure by 30% at the same time.[9] This reduction in cerebral pressure may be responsible for the remarkable efficacy in a group of headaches that is referred to as "indometacin-responsive headaches", such as idiopathic stabbing headache, chronic paroxysmal hemicranial, and exertional headaches.[20] On the other hand, the activation of superior salivary nucleus in the brainstem is used to stimulate the trigeminal autonomic reflex arc, causing a type of headache called trigeminal autonomic cephalgia. Indometacin inhibits the superior salivatory nucleus, thus relieving this type of headache.[9]

    Prostaglandins also cause uterine contractions in pregnant women. Indometacin is an effective tocolytic agent,[21] able to delay premature labor by reducing uterine contractions through inhibition of prostaglandin synthesis in the uterus and possibly through calcium channel blockade.

    Indometacin readily crosses the placenta and can reduce fetal urine production to treat polyhydramnios. It does so by reducing renal blood flow and increasing renal vascular resistance, possibly by enhancing the effects of vasopressin on the fetal kidneys.

    Other modes of action for indometacin are:

    Nomenclature[edit]

    Indometacin is the INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and JANTooltip Japanese Accepted Name of the drug while indomethacin is the USANTooltip United States Approved Name, and former AANTooltip Australian Approved Name and BANTooltip British Approved Name.[23][24][25]

    References[edit]

    1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  • ^ a b c Brayfield A, ed. (14 January 2014). "Indometacin". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 22 June 2014.
  • ^ "TGA Approved Terminology for Medicines, Section 1 – Chemical Substances" (PDF). Therapeutic Goods Administration, Department of Health and Ageing, Australian Government. July 1999. p. 70.
  • ^ Hart FD, Boardman PL (October 1963). "Indomethacin: A New Non-steroid Anti-inflammatory Agent". British Medical Journal. 2 (5363): 965–70. doi:10.1136/bmj.2.5363.965. PMC 1873102. PMID 14056924.
  • ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 517. ISBN 9783527607495.
  • ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  • ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  • ^ "Indomethacin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  • ^ a b c d e f g h i Lucas S (February 2016). "The Pharmacology of Indomethacin". Headache. 56 (2): 436–46. doi:10.1111/head.12769. PMID 26865183. S2CID 205160729.
  • ^ a b c d e f g h i j k Dodick DW (February 2004). "Indomethacin-responsive headache syndromes". Current Pain and Headache Reports. 8 (1): 19–26. doi:10.1007/s11916-004-0036-6. PMID 14731379. S2CID 24393617.
  • ^ Sekar KC, Corff KE (May 2008). "Treatment of patent ductus arteriosus: indomethacin or ibuprofen?". Journal of Perinatology. 28 (Suppl 1): S60-2. doi:10.1038/jp.2008.52. PMID 18446180. S2CID 5553768.
  • ^ "INDOMETHACIN". Hazardous Substances Data Bank (HSDB). National Library of Medicine's TOXNET. Retrieved 4 April 2013.
  • ^ Akbarpour F, Afrasiabi A, Vaziri ND (June 1985). "Severe hyperkalemia caused by indomethacin and potassium supplementation". Southern Medical Journal. 78 (6): 756–7. doi:10.1097/00007611-198506000-00039. PMID 4002013.
  • ^ Enzensberger C, Wienhard J, Weichert J, Kawecki A, Degenhardt J, Vogel M, et al. (August 2012). "Idiopathic constriction of the fetal ductus arteriosus: three cases and review of the literature". Journal of Ultrasound in Medicine. 31 (8): 1285–91. doi:10.7863/jum.2012.31.8.1285. PMID 22837295. S2CID 6798504.[permanent dead link]
  • ^ a b "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  • ^ a b "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  • ^ Ferreira SH, Moncada S, Vane JR (June 1971). "Indomethacin and aspirin abolish prostaglandin release from the spleen". Nature. 231 (25): 237–9. doi:10.1038/newbio231237a0. PMID 5284362.
  • ^ Laprairie RB, Mohamed KA, Zagzoog A, Kelly ME, Stevenson LA, Pertwee R, et al. (18 October 2019). "Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling". Frontiers in Molecular Neuroscience. 12: 257. doi:10.3389/fnmol.2019.00257. PMC 6813218. PMID 31680861.
  • ^ Castellano AE, Micieli G, Bellantonio P, Buzzi MG, Marcheselli S, Pompeo F, et al. (November 1998). "Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications". Cephalalgia. 18 (9): 622–30. doi:10.1046/j.1468-2982.1998.1809622.x (inactive 7 February 2024). PMID 9876886.{{cite journal}}: CS1 maint: DOI inactive as of February 2024 (link)
  • ^ Dowd FJ, Johnson B, Mariotti A. "Chapter 23, Drugs for Treating Orofacial Pain Syndromes.". Pharmacology and Therapeutics for Dentistry-E-Book. Elsevier Health Sciences; 2016 Sep 3. pp. 384–5.
  • ^ Giles W, Bisits A (October 2007). "Preterm labour. The present and future of tocolysis". Best Practice & Research. Clinical Obstetrics & Gynaecology. 21 (5): 857–68. doi:10.1016/j.bpobgyn.2007.03.011. PMID 17459777.
  • ^ Draper MP, Martell RL, Levy SB (1997). "Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein". British Journal of Cancer. 75 (6): 810–5. doi:10.1038/bjc.1997.145. PMC 2063393. PMID 9062400.
  • ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 684–. ISBN 978-1-4757-2085-3.
  • ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 550–. ISBN 978-3-88763-075-1.
  • ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 153–. ISBN 978-94-011-4439-1.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Indometacin&oldid=1220689057"

    Categories: 
    3α-Hydroxysteroid dehydrogenase inhibitors
    Antigout agents
    Carboxamides
    Chloroarenes
    Hepatotoxins
    Indole ethers at the benzene ring
    Nonsteroidal anti-inflammatory drugs
    Tocolytics
    Aromatic ketones
    Methoxy compounds
    Hidden categories: 
    All articles with dead external links
    Articles with dead external links from December 2017
    Articles with permanently dead external links
    Source attribution
    CS1 maint: DOI inactive as of February 2024
    Articles with short description
    Short description is different from Wikidata
    Use dmy dates from January 2024
    Infobox drug with local INN variant
    Drugs with non-standard legal status
    ECHA InfoCard ID from Wikidata
    Drugboxes which contain changes to watched fields
     



    This page was last edited on 25 April 2024, at 09:16 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki